Dr. Fabio Marino

Dr. Fabio Marino

Assistant Professor
Biomolecular Mass Spectrometry and Proteomics
f.marino@uu.nl
December 2024- Present   Utrecht University

Assistant professor at department of Pharmacy, UIPS, Utrecht University, Biomulecular Mass Spectrometry and Proteomics, The Netherlands Proteomics Center, Oncode Accelerator.

2019-End 2024   Enara Bio (Oxford, UK)

Director of mass spectrometry and head of antigen discovery:

• Identification and validation of a set of antigens shared across tumours for internal development of T-cell based therapies. 

• Identification and validation of multiple antigens leading to external in partnerships, novel investments and creating high value clinical candidates for the company for a range of immunotherapies.

 

2016-2019 Ludwig Cancer Institute (Lausanne, Switzerland)

Post-Doctoral research:

• Implementation of an innovative, semi-automatized immunopeptidomics MS-based sample processing for analysis of HLA class I and II ligandomes. 

• Insight into the HLA ligandome and the antigen processing and presentation machinery of APCs in response to differential stimuli for re-directing epitope presentation. 

• Studying of mechanisms of immunogenicity of dendritic cell-based vaccination loaded with tumor lysates. 

• MS-based antigen discovery of tumor tissues for cancer immunotherapy

 

End 2011-2016 Biomolecular Proteomics and Mass Spectrometry group (Utrecht)

PhD/Post-Doctoral research:

• Study of proteasome-generated spliced peptide on HLA class I immunopeptidome. 

• Characterization of the molecular binding mechanisms of phospho moieties harboring HLA B40:02 complexes. 

• Study of the effect of Arginine methylation and dimethylation on HLA class I- peptide complexes. 

• Quantitative profiling of monocytes stimulated with different vaccine adjuvants. 

• Study of unexpected extended O-GlcNAc modifications on HLA class I-bound peptides.

• Establishment and characterization of a high performing 2D SCX-RP UHPLC-MS/MS platform for increasing to extend the proteome coverage of complex peptide mixtures. 

• Development of a proteomic in vitro assay for identifying the consensus motifs of kinases. 

• Mapping the HLA-DR ligandome of human monocyte-derived dendritic cells. 

• Establishment of a complete proteomic workflow to study asymmetrical and symmetrical arginine dimethylation. 

• Exploring different kind of workflows for middle-down proteomic approaches.